BioCardia Inc (BCDA) Stock Analysis
Verdict: AVOID
Existential dilution and a ~4-month cash runway overshadow Phase I/II clinical pipeline progress despite insider buying.
Investment score: 30/100
Analysis as of
Is BioCardia Inc stock worth reviewing? The TradeMates thesis
The TradeMates model views BCDA as a high-risk micro-cap biotech facing an immediate cash crunch. While CEO insider buying provides a positive micro-signal, a cash runway of under 4 months makes major equity dilution highly probable.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 65/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
BioCardia Inc opportunities and risks
What speaks for BCDA
- Phase I/II clinical trials for CardiAMP and allogeneic cell therapies target multi-billion dollar heart failure markets.
What speaks against BCDA
- Existential liquidity shortfall and cash runway of under 4 months.
Frequently asked questions about BioCardia Inc (BCDA)
Is BCDA stock a good investment?
The TradeMates model rates BioCardia Inc as AVOID with an investment score of 30/100. The TradeMates model views BCDA as a high-risk micro-cap biotech facing an immediate cash crunch. While CEO insider buying provides a positive micro-signal, a cash runway of under 4 months makes major equity dilution highly probable. This is algorithmic model output, not personal investment advice.
Is BCDA stock a buy?
The TradeMates model verdict for BCDA is AVOID with an investment score of 30/100. Treat this as a model signal to review, not a personal buy recommendation.